How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,648 results for

aspirin and gastrointestinal bleeding

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Canadian Stroke Best Practice recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events

% more people die of heart conditions, stroke or vascular cognitive impairment than die from all cancers combined. 1 The benefits of acetylsalicylic acid (ASA) for secondary pre- vention of atherosclerotic cardiovascular disease are well estab- lished. In contrast, although low-dose ASA therapy for primary prevention of atherosclerotic cardiovascular disease was once commonly recommended, this practice is now being recon- sidered in light of recent evidence. Three large randomized con- trolled trials (...) -dose ASA reduces the risk of vascular events including myocardial infarction, stroke and vascular death in patients who have had a previous vascular event. The Antithrombotic Trialists’ Collaboration (2002) has meta-analyzed data from many large trials showing consistent effects of ASA on preventing recurrent cardiovascular events. 11 For example, treatment with ASA instead Box 1: Recommendations for the use of acetylsalicylic acid (ASA) in the prevention of vascular events* Secondary prevention

2020 CPG Infobase

2. Misoprostol Heals Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding Full Text available with Trip Pro

Misoprostol Heals Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding There is no effective treatment for aspirin-induced small bowel ulcer bleeding. We performed a double-blind, randomized, placebo-controlled trial to determine whether misoprostol can heal small bowel ulcers in patients with small bowel bleeding who require continuous aspirin therapy.We performed a prospective study of 84 aspirin users with small bowel bleeding who required continued aspirin therapy in Hong Kong (...) [range, 0-25]) than in the placebo group (from 7 [range, 1-29] to 4 [range, 0-19] (P = .005).In a double-blind, randomized, placebo-controlled trial, we found misoprostol to be superior to placebo in promoting healing of small bowel ulcers among aspirin users complicated by small bowel ulcer bleeding who require continuous aspirin therapy. However, use of misoprostol alone would provide only limited protection against aspirin on the small bowel. ClinicalTrials.gov ID NCT01998776.Copyright © 2018 AGA

2018 EvidenceUpdates

3. Rivaroxaban (Xarelto) - Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients

acid) reduced the incidence of a composite outcome that included stroke, cardiovascular death and myocardial infarction, mainly due to reductions in stroke and cardiovascular death. It also increased the incidence of major bleeding. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication Co-administered with acetylsalicylic acid (aspirin) for the prevention of atherothrombotic events in adult patients with: - coronary artery disease, or - symptomatic peripheral artery (...) submission rivaroxaban (Xarelto ® ) is accepted for restricted use within NHSScotland. Indication under review: Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with: - coronary artery disease, or - symptomatic peripheral artery disease at high risk of ischaemic events. SMC restriction: use in patients with stable coronary artery disease that does not require dual antiplatelet therapy. Addition of rivaroxaban to low-dose aspirin (acetylsalicylic

2019 Scottish Medicines Consortium

4. Acetyl Salicylic Acid (ASA)

Acetyl Salicylic Acid (ASA) © 2015 Thrombosis Canada Page 1 of 4 ACETYL SALICYLIC ACID (ASA) OBJECTIVE: To provide information on the use of acetyl salicylic acid in the prevention of vascular thromboembolic events. BACKGROUND: Acetyl salicylic acid (ASA) is well-established in the management of acute myocardial infarction and in the secondary prevention of cardiovascular disease among both men and women, based on large randomized trials. More recently, its role in the prevention of recurrent (...) venous thromboembolism has been demonstrated. The net benefit of ASA use depends on weighing the anticipated reduction in cardiovascular events against the increased risk of gastrointestinal bleeding. MECHANISM OF ACTION OF ASA: ASA irreversibly inhibits platelet aggregation by inhibiting thromboxane A 2 (TxA 2 ) synthesis. INDICATIONS FOR ASA: Antiplatelet therapy is recommended for all patients with the following, unless contraindicated: 1) Cardiac: For all patients with symptomatic coronary artery

2015 Thrombosis Interest Group of Canada

5. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis

Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

6. Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding Full Text available with Trip Pro

example seeking to emulate a "per-protocol" association between continuous versus never use of low-dose acetylsalicylic acid (ASA) and major bleeding (e.g., cerebral hemorrhage or gastrointestinal bleeding).Danish medical registry data from 2004 to 2011 were used to construct two analytic cohorts. In Cohort 1, we used information about future redemption of low-dose ASA prescriptions to identify cohorts of continuous and never-ASA users. In Cohort 2, we identified ASA initiators and non-initiators (...) Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding A principle of cohort studies is that cohort membership is defined by current rather than future exposure information. Pharmacoepidemiologic studies using existing databases are vulnerable to violation of this principle. We evaluated the impact of using data on future redemption of prescriptions to determine cohort membership, motivated by a published

2017 Clinical epidemiology

7. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial. Full Text available with Trip Pro

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial. The incidence of obscure gastrointestinal bleeding, which originates from the small bowel and is mainly associated with the use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), is rising. We assessed the efficacy and safety of misoprostol for the treatment of small bowel ulcers (...) and erosions in patients taking low-dose aspirin or NSAIDs with obscure gastrointestinal bleeding.In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients (aged ≥18 years) with small bowel ulcers who were taking low-dose aspirin, NSAIDs, or both for a minimum of 4 weeks, at University Hospital Crosshouse (Kilmarnock, UK). Eligible patients had evidence of obscure gastrointestinal bleeding (iron deficiency anaemia, a decrease in haemoglobin concentration of ≥20 × 103 mg/L

2019 The lancet. Gastroenterology & hepatology Controlled trial quality: predicted high

8. The effect of low-dose aspirin on colorectal cancer prevention and gastrointestinal bleeding according to bodyweight and body mass index: Analysis of UK primary care data. Full Text available with Trip Pro

The effect of low-dose aspirin on colorectal cancer prevention and gastrointestinal bleeding according to bodyweight and body mass index: Analysis of UK primary care data. Meta-analysis of trial data suggests that in primary cardiovascular disease (CVD) prevention bodyweight modifies low-dose aspirin's effects on colorectal cancer (CRC) and major bleeding risk. We sought to investigate whether these effects are seen in patients with or without CVD in routine clinical practice by undertaking sub (...) -analyses of data from two cohort studies with nested-case-control analyses.We followed ~200,000 new users of low-dose aspirin (75-300 mg/day) and a matched cohort of non-users to identify incident cases of CRC/upper gastrointestinal bleeding (UGIB). Adjusted relative risks (RRs) with 95% confidence intervals (CIs) were calculated for current vs. non-use of low-dose aspirin using logistic regression stratified by bodyweight/body mass index (BMI) strata.RRs (95% CIs) for CRC by bodyweight were: 0.60

2019 International journal of cardiology

9. Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom. Full Text available with Trip Pro

Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom. Risks of low-dose aspirin-associated upper and lower gastrointestinal bleeds (UGIB/LGIB) may vary by severity and presence of cardiovascular disease (CVD). No study has quantified these risks for UGIB and LGIB in the same real-world study population.Using UK primary care data, 199,049 new (...) users of low-dose aspirin (75-300 mg/day) and 1:1 matched non-users were followed to identify incident UGIB (N = 1843)/LGIB (N = 2763) cases. Nested case-control analyses compared current low-dose aspirin vs. non-use on UGIB/LGIB risk.Adjusted incidence rate ratios (ORs; 95% CIs) were 1.62 (1.42-1.86) for non-fatal UGIB, 1.63 (1.47-1.81) for non-fatal LGIB, 0.77 (0.51-1.16) for fatal UGIB, 1.29 (0.50-3.36) for fatal LGIB. For hospitalizations, adjusted ORs (95% CIs) were 1.55 (1.32-1.81) for UGIB

2019 Annals of Medicine

10. CRACKCast E095 – Large Intestine

abscess drainage; Fistulas and strictures may need surgical correction after the acute phase. Definitive: Some surgeons may elect to do a single stage laparoscopic resection to remove sections of the colon Complications: Complicated diverticulitis: Any extension of inflammation beyond the pericolonic fat Abscess formation Peritonitis Intestinal obstruction (inflammatory ileus) Fistula formation (to the bladder) Bleeding – severe hemorrhage Lower GI bleeding – 40% of it is caused by diverticulae (...) that people with IBS have abnormal electric rhythmic patterns and abnormal responses to stimulation. Often associated with anxiety, depression, FM, CFS, chronic pelvic pain, sexual abuse, menstrual cycle variations. Routine laboratory studies (complete blood count, chemistries) are normal in IBS. “Alarm” or atypical symptoms which are not compatible with IBS include: Rectal bleeding Nocturnal or progressive abdominal pain Weight loss Laboratory abnormalities such as anemia, elevated inflammatory markers

2017 CandiEM

11. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group

pylori eradication and required con- tinued antiplatelet therapy (acetylsalicylic acid [ASA]) (88). A meta-analysis of 2 trials showed that PPIs plus ASA reduced rebleeding rates versus clopidogrel alone (RR, 0.07 [CI, 0.01 to 0.34]) in patients with pre- vious ASA-associated ulcer bleeding who did not have H pylori infection or who had it successfully eradicated (90, 91). In patients with previous ASA-associated ulcer bleeding, trials found no difference between PPIs and eradication treatment (...) resuscitation to increase blood pressure to normal values may exacerbate blood loss, disrupt coagulation, andincreasemortality(23,24).Thealternativeisrestric- tive or hypotensive resuscitation, in which ?uid is given but the target end point is less than normotension. A Cochrane systematic review included 6 randomized tri- als that examined timing and volume of ?uid adminis- tration in 2128 patients with bleeding. Trials were het- erogeneous regarding patient types, clinical settings, types of ?uids

2020 Canadian Association of Gastroenterology

12. Risk of Gastrointestinal Bleeding and Benefit from Colorectal Cancer Reduction from Long-term Use of Low Dose Aspirin. A Retrospective Study of 612,509 Patients. (Abstract)

Risk of Gastrointestinal Bleeding and Benefit from Colorectal Cancer Reduction from Long-term Use of Low Dose Aspirin. A Retrospective Study of 612,509 Patients. Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, is well known to protect against development of colorectal cancer (CRC) but increases risk of gastrointestinal bleeding (GIB). This cohort study aims to evaluate the benefit of low-dose aspirin to prevent CRC and its associated risk of GIB.A (...) hazard ratio = 1.09; 95% confidence interval = 1.00 to 1.19). Subgroup analyses showed the use of acid-secreting agents significantly reduced aspirin-induced mortality.The long-term use of aspirin reduces both incidence and mortality of CRC and at the same time increases incidence and mortality risk of GIB. With combination use of acid-secreting agents, the bleeding risk can be reduced.© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

2018 Journal of gastroenterology and hepatology

13. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. (Abstract)

in the clopidogrel plus aspirin group and 1 in the aspirin alone group); 3 of the 4 were intracranial. There were 7 intracranial hemorrhages (0.1%); 5 were in the clopidogrel plus aspirin group and 2 in the aspirin plus placebo group. The most common location of major hemorrhages was in the gastrointestinal tract.The risk for major hemorrhages in patients receiving either clopidogrel plus aspirin or aspirin alone after TIA or minor AIS was low. Nevertheless, treatment with clopidogrel plus aspirin increased (...) Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone.To characterize the frequency and kinds of major hemorrhages in the Platelet

2019 JAMA neurology Controlled trial quality: predicted high

14. Clopidogrel/Acetylsalicylic acid Teva

demand in the presence of a high-grade fixed coronary obstruction, due to increased myocardial oxygen and nutrition requirements, such as those resulting from exertion, emotional stress, or physiologic stress (e.g., from dehydration, blood loss, hypotension, infection, thyrotoxicosis, or surgery). This Marketing Authorisation Application concerns clopidogrel/acetylsalicylic acid tablets containing clopidogrel (75 mg) and acetylsalicylic acid (ASA) (75 mg or 100 mg). Clopidogrel / Acetylsalicylic acid (...) of the extensive data available on the use of combined individual medicinal products at the dosage now being applied for in the Clopidogrel/ASA application. Safety pharmacology Safety pharmacology studies with clopidogrel did not reveal any relevant effect to the central nervous, cardiovascular, respiratory, gastrointestinal and renal systems. The targets for toxicity of acetylsalicylic acid have been identified in nonclinical studies and clinical experience has put these findings into context. Medicinal

2014 European Medicines Agency - EPARs

15. Impact of perioperative aspirin continuation on bleeding complications in laparoscopic colorectal cancer surgery: a propensity score-matched analysis. (Abstract)

Impact of perioperative aspirin continuation on bleeding complications in laparoscopic colorectal cancer surgery: a propensity score-matched analysis. In laparoscopic surgery for colorectal cancer (CRC) for patients who receive antiplatelet therapy (APT), it remains unclear whether APT should be continued or temporarily withdrawn. We investigated the safety of perioperative aspirin continuation, specifically focused on bleeding complications.We performed retrospective analysis utilizing (...) based on our institutional committee-approved guidelines for antithrombotic management.In PSM cohorts, all patient demographics were comparable between the groups. Regarding intraoperative outcomes, we found no significant difference in operation duration (p = 0.969), blood loss (p = 0.068), and blood transfusion (p = 0.517). Postoperative overall morbidity was 20.0% and 13.3% in the cAPT and non-cAPT groups, respectively (p = 0.195). The incidence of bleeding complications was also comparable

2020 Surgical endoscopy

16. Diagnosis and management of acute lower gastrointestinal bleeding

and has no requirement for bowel preparation. As bright or dark red blood per rectum or blood mixed in with stool and haemodynamic instability may be a presentation of UGIB, senior clinical discussion should consider the appropriate- ness of upper GI endoscopy before proceeding directly to CTA in unstable patients. Bright red rectal bleeding may be indicative of an anorectal source of haemorrhage. Patients with this pres- entation should undergo direct anorectal inspection. If anoscopy and CTA do (...) endoscopy (VCE) is a non-invasive investigation that permits examination of the entire length of the small bowel in 79–90% of patients. 60 This modality is increasingly used in patients presenting with overt-obscure GI bleeding who have had negative adequate upper and lower GI endoscopy. Three RCTs support the use of VCE in patients with overt-obscure GI bleeding (documented blood loss, no cause found) and no source identified on upper and lower GI endoscopy, reporting a higher diagnostic yield than

2019 British Society of Gastroenterology

17. CRACKCast E30 – GI Bleeding

CRACKCast E30 – GI Bleeding CRACKCast E30 - GI Bleeding - CanadiEM CRACKCast E30 – GI Bleeding In , by Adam Thomas March 9, 2017 This episode of CRACKCast covers Rosen’s Chapter 30, GI Bleeding. This episode gives us a solid approach to the workup and management for GI bleeds. Showntoes – Rosen’s in perspective: Large burden of disease More than 1 million admissions in US per year. Risk factors: Medication use: Aspirin NSAIDs Steroids Anticoagulants (warfarin, heparin) Chemotherapeutic agents (...) cancer Duodenal ulcers Gastric ulcers Esophagitis Gastric erosion Esophageal varices Mallory-Weiss tears 2) List 5 causes of LGIB in adults and pediatrics Rosen’s 8 th edition. Table 30 -2. Adult Pediatrics Diverticular disease Angiodysplasia Colitis (inflammatory, infectious, ischemic) Anorectal sources Neoplasm Upper GI bleeding Anorectal fissure Infectious colitis Inflammatory bowel disease Juvenile polyps Intussusception Meckel’s diverticulum 3) Describe your management approach for severe UGIB 4

2017 CandiEM

18. Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING]

the feasibility and safety of the HemoPill acute and its implementation procedure as well as, the definition of measurable parameters and thresholds for blood detection. Within this clinical trial, initial clinical data on the performance of the HemoPill acute capsule were collected. Condition or disease Intervention/treatment Phase Upper GI Bleeding Diagnostic Test: HemoPill acute Not Applicable Detailed Description: The clinical trial entitled "Detection of upper gastrointestinal (GI) bleeding with a novel (...) Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING] Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING] - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

19. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for <i>Helicobacter pylori</i>: a territory-wide cohort study. Full Text available with Trip Pro

Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study. The risk of GI bleeding (GIB) in aspirin users after Helicobacter pylori (HP) eradication remains poorly defined. We characterised the incidences and temporal trends of hospitalisations for all GIB in aspirin users after HP eradication therapy.Based on a territory-wide health database, we (...) of hospitalisation for all GIB in new, chronic and non-users was 10.4, 7.2 and 4.6 per 1000 person-years, respectively. Upper and lower GIB accounted for 34.7% and 45.3% of all bleeding, respectively. Compared with chronic users, new users had a higher risk of GIB (HR with propensity score matching: 1.89; 95% CI 1.29 to 2.70). Landmark analysis showed that the increased risk in new aspirin users was only observed in the first 6 months for all GIB (HR 2.10, 95% CI 1.41 to 3.13) and upper GIB (HR 2.52, 95% CI 1.38

2019 Gut

20. Etiology and Long-term Rebleeding of Endoscopic Ulcerative Lesions in the Small Bowel in Patients with Obscure Gastrointestinal Bleeding: A Multicenter Cohort Study. (Abstract)

Etiology and Long-term Rebleeding of Endoscopic Ulcerative Lesions in the Small Bowel in Patients with Obscure Gastrointestinal Bleeding: A Multicenter Cohort Study. Among patients with obscure gastrointestinal bleeding (OGIB), endoscopic ulcerative lesions in the small bowel have diverse etiologies and often cause rebleeding. Certain characteristics of patients or ulcerations may be reasonable indications for diagnostic balloon-assisted endoscopy (BAE) to assess etiology and may be risks (...) , rebleeding occurred in 14 (21%) patients during a mean follow-up period of 17 months. Aspirin use and multiple ulcerations were significant predictors of rebleeding (P < 0.05).When we manage small bowel ulcerative lesions in OGIB patients, a single ulceration is a reasonable indication for the diagnostic BAE. The rebleeding rate was lower for single ulcerations than for multiple ulcerations.© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

2017 Journal of gastroenterology and hepatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>